NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024
Susan M. Swetter, Douglas Buckner Johnson, Mark R. Albertini et al. · Journal of the National Comprehensive Cancer Network · 2024
The NCCN Guidelines for Cutaneous Melanoma (termed Melanoma: Cutaneous) provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients. These NCCN Guidelines Insights focus on the update to neoadjuvant systemic therapy options and summarize the new clinical data evaluated by the NCCN panel for the recommended therapies in Version 2.2024 of the NCCN Guidelines for Cutaneous Melanoma.
Cited by 158 works. doi:10.6004/jnccn.2024.0036
Authors
- Susan M. Swetter
- Douglas Buckner Johnson
- Mark R. Albertini
- Christopher Andrew Barker
- Sarah B. Bateni
- Joel Micah Baumgartner
- Shailender Bhatia
- Christopher Keram Bichakjian
- Genevieve Marie Boland
- Sunandana Chandra
- Bartosz Chmielowski
- Dominick J. DiMaio
- Roxana Stefania Dronca
- Ryan Courtney Fields
- Martin D. Fleming
- Anjela Galan
- Samantha R. Guild
- John Robert Hyngstrom
- Giorgos Constantine Karakousis
- Kari Lynn Kendra
References
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
- Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure
- Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040
- Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
- Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
- Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma